| scholarly article | Q13442814 |
| P50 | author | Dario Alessi | Q5222818 |
| Nathanael Gray | Q28112823 | ||
| Mario Niepel | Q38155560 | ||
| Peter K. Sorger | Q42127905 | ||
| Tyzoon K Nomanbhoy | Q125308557 | ||
| Francisco Inesta-Vaquera | Q125308704 | ||
| P2093 | author name string | Jarrod A Marto | |
| Ting Xie | |||
| Scott B Ficarro | |||
| Jianming Zhang | |||
| Thomas Machleidt | |||
| Taebo Sim | |||
| Philip V LoGrasso | |||
| Tinghu Zhang | |||
| Hajeung Park | |||
| John D Laughlin | |||
| NamDoo Kim | |||
| Matt Patricelli | |||
| P2860 | cites work | Signal transduction by tumor necrosis factor mediated by JNK protein kinases | Q24308037 |
| JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain | Q24308838 | ||
| p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system | Q24310112 | ||
| The selectivity of protein kinase inhibitors: a further update | Q24654622 | ||
| Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. | Q24805693 | ||
| N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3 | Q27643446 | ||
| Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors | Q27644604 | ||
| Selectivity-determining residues in Plk1 | Q27649061 | ||
| Synthesis, Biological Evaluation, X-ray Structure, and Pharmacokinetics of Aminopyrimidine c-jun-N-terminal Kinase (JNK) Inhibitors | Q27658377 | ||
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M | Q27658766 | ||
| The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307) | Q28139056 | ||
| Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action | Q28199220 | ||
| Mammalian MAP kinase signalling cascades | Q28204140 | ||
| JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation | Q28243308 | ||
| A quantitative analysis of kinase inhibitor selectivity | Q28264038 | ||
| Differential regulation and properties of MAPKs | Q28301932 | ||
| SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase | Q28364720 | ||
| Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions | Q28375843 | ||
| Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions | Q29547189 | ||
| Targeting cancer with small molecule kinase inhibitors | Q29547395 | ||
| Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation | Q29614227 | ||
| Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases | Q29614338 | ||
| A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 | ||
| Rational design of inhibitors that bind to inactive kinase conformations | Q29617558 | ||
| A central role for JNK in obesity and insulin resistance | Q29619778 | ||
| Targeting RSK: an overview of small molecule inhibitors | Q33376012 | ||
| Adaptive informatics for multifactorial and high-content biological data | Q33880802 | ||
| The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. | Q34014364 | ||
| A structure-guided approach to creating covalent FGFR inhibitors | Q34061522 | ||
| cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance | Q34285542 | ||
| Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. | Q34573054 | ||
| Functional interrogation of the kinome using nucleotide acyl phosphates | Q34599227 | ||
| Quantitative reactivity profiling predicts functional cysteines in proteomes | Q34682241 | ||
| Phosphorylation of c-jun mediated by MAP kinases. | Q34947174 | ||
| JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease | Q35031088 | ||
| Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. | Q35575978 | ||
| Emerging treatments for asthma | Q35581140 | ||
| JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease | Q35736273 | ||
| Mitogen-activated protein kinases and asthma | Q35865902 | ||
| Inhibitors of the tyrosine kinase signaling cascade for asthma | Q36134371 | ||
| Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants | Q36300027 | ||
| Identification of a new JNK inhibitor targeting the JNK-JIP interaction site | Q36938538 | ||
| High-throughput kinase profiling as a platform for drug discovery | Q37135359 | ||
| Targeted covalent drugs of the kinase family | Q37770660 | ||
| MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo | Q38431323 | ||
| Inhibitors of c-jun-N-terminal kinase (JNK). | Q38476233 | ||
| Irreversible Nek2 kinase inhibitors with cellular activity | Q39533198 | ||
| High-throughput cellular assays for regulated posttranslational modifications | Q40062283 | ||
| Structural bioinformatics-based design of selective, irreversible kinase inhibitors | Q40307105 | ||
| DataPflex: a MATLAB-based tool for the manipulation and visualization of multidimensional datasets | Q42641977 | ||
| Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. | Q42750517 | ||
| Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis | Q43937884 | ||
| Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor | Q43948616 | ||
| Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase | Q44881257 | ||
| Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents | Q44958088 | ||
| A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. | Q45126637 | ||
| Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway | Q45750046 | ||
| c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress | Q46291354 | ||
| Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. | Q46586116 | ||
| A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra | Q52227970 | ||
| ERK5 pathway regulates the phosphorylation of tumour suppressor hDlg during mitosis | Q53311661 | ||
| SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence | Q73586335 | ||
| P433 | issue | 1 | |
| P921 | main subject | clinical chemistry | Q849994 |
| drug discovery | Q1418791 | ||
| P304 | page(s) | 140-54 | |
| P577 | publication date | 2012-01-27 | |
| P1433 | published in | Chemistry and Biology | Q15758410 |
| P1476 | title | Discovery of Potent and Selective Covalent Inhibitors of JNK | |
| P478 | volume | 19 |
| Q28828468 | (±)-Japonones A and B, two pairs of new enantiomers with anti-KSHV activities from Hypericum japonicum |
| Q46423964 | A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. |
| Q47113193 | A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. |
| Q89625823 | A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells |
| Q44090999 | A public-private partnership to unlock the untargeted kinome |
| Q100503778 | AP-1 and TGFß cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma |
| Q51764245 | Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway |
| Q57176106 | BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells |
| Q40033023 | Beta Interferon Production Is Regulated by p38 Mitogen-Activated Protein Kinase in Macrophages via both MSK1/2- and Tristetraprolin-Dependent Pathways. |
| Q97421909 | C-Jun N-terminal kinase inhibitors: Structural insight into kinase-inhibitor complexes |
| Q50938874 | Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors |
| Q40688076 | Covalent Inhibition of HIV-1 Integrase by N-Succinimidyl Peptides |
| Q29248430 | Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions |
| Q60193666 | Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. |
| Q37275810 | Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors |
| Q91341088 | Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling |
| Q27027983 | Developing Irreversible Inhibitors of the Protein Kinase Cysteinome |
| Q38763094 | Development of Selective Covalent Janus Kinase 3 Inhibitors. |
| Q27723532 | Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3 |
| Q27684879 | Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2) |
| Q42594318 | Drug resistance in cancer: molecular evolution and compensatory proliferation |
| Q35135920 | E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin |
| Q27001584 | Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? |
| Q36693046 | Fibroblast Growth Factor 21 Mediates Glycemic Regulation by Hepatic JNK |
| Q92174328 | Genome-scale screens identify JNK-JUN signaling as a barrier for pluripotency exit and endoderm differentiation |
| Q37686982 | HSF1 critically attunes proteotoxic stress sensing by mTORC1 to combat stress and promote growth |
| Q38761120 | Heat Shock Factor 1 Is a Substrate for p38 Mitogen-Activated Protein Kinases |
| Q26863735 | IRAK signalling in cancer |
| Q36377998 | Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations |
| Q56889371 | Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data |
| Q39166310 | Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. |
| Q35731654 | Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility |
| Q52671165 | Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition |
| Q48505281 | Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia |
| Q60049334 | Inhibition of JNK signaling in the Asian malaria vector Anopheles stephensi extends mosquito longevity and improves resistance to Plasmodium falciparum infection |
| Q35932496 | Inhibitor design against JNK1 through e-pharmacophore modeling docking and molecular dynamics simulations. |
| Q33955160 | Inhibitory and mechanistic investigations of oxo-lipids with human lipoxygenase isozymes. |
| Q92407109 | Integrative discovery of treatments for high-risk neuroblastoma |
| Q90661538 | Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy |
| Q38012518 | Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks |
| Q47118502 | JNK Promotes Epithelial Cell Anoikis by Transcriptional and Post-translational Regulation of BH3-Only Proteins |
| Q38797029 | JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells |
| Q35822826 | JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. |
| Q39017426 | JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer |
| Q27023869 | JNK signalling in cancer: in need of new, smarter therapeutic targets |
| Q90198886 | JNK-IN-8, a c-Jun N-terminal kinase inhibitor, improves functional recovery through suppressing neuroinflammation in ischemic stroke |
| Q58544845 | JNK-mediated phosphorylation of SARM1 regulates NAD cleavage activity to inhibit mitochondrial respiration |
| Q37705086 | JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention. |
| Q41193883 | JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21. |
| Q37233445 | JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma |
| Q38701688 | JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines |
| Q91631146 | Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases |
| Q35680832 | LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal |
| Q39292273 | Manipulating JNK signaling with (--)-zuonin A. |
| Q55318272 | Matrix stiffness-upregulated LOXL2 promotes fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist pre-metastatic niche formation. |
| Q92631849 | Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer |
| Q27865268 | Mitogen-activated protein kinases in innate immunity |
| Q55375334 | Mycophenolate Mofetil induces c-Jun-N-terminal kinase expression in 22Rv1 cells: an impact on androgen receptor signaling. |
| Q64892288 | Network pharmacology-based identification of potential targets of the flower of Trollius chinensis Bunge acting on anti-inflammatory effectss. |
| Q101455784 | Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins |
| Q38693434 | New drug design with covalent modifiers. |
| Q39289226 | Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia |
| Q43480924 | Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A. |
| Q26862544 | PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms |
| Q42164005 | Peroxiredoxin 6 mediates Gαi protein-coupled receptor inactivation by cJun kinase. |
| Q34355529 | Post-translational regulation of mitogen-activated protein kinase phosphatase (MKP)-1 and MKP-2 in macrophages following lipopolysaccharide stimulation: the role of the C termini of the phosphatases in determining their stability |
| Q38450704 | Profiling Protein Kinases and Other ATP Binding Proteins in Arabidopsis Using Acyl-ATP Probes |
| Q30274823 | Profiling Subcellular Protein Phosphatase Responses to Coxsackievirus B3 Infection of Cardiomyocytes |
| Q41897831 | Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation |
| Q30397636 | Pseudokinases: update on their functions and evaluation as new drug targets |
| Q42553470 | Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. |
| Q91796904 | Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening |
| Q90424107 | Reactive oxygen species (ROS) generation is stimulated by κ opioid receptor activation through phosphorylated c-Jun N-terminal kinase and inhibited by p38 mitogen-activated protein kinase (MAPK) activation |
| Q35174581 | Redox regulation of protein kinases |
| Q42772188 | Regulation of axon growth by the JIP1-AKT axis |
| Q44062393 | Reversible covalent inhibition of eEF-2K by carbonitriles. |
| Q51653926 | Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development |
| Q50027324 | Role of c-Jun-N-terminal kinase in pregnane X receptor-mediated induction of human cytochrome P4503A4 in vitro |
| Q58767772 | Role of the MAPK/cJun NH-terminal kinase signaling pathway in starvation-induced autophagy |
| Q37660289 | S100A4 Elevation Empowers Expression of Metastasis Effector Molecules in Human Breast Cancer |
| Q52720673 | STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle. |
| Q27702605 | Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine |
| Q93028197 | Selective inhibitors for JNK signalling: a potential targeted therapy in cancer |
| Q34193885 | Selective mitogen activated protein kinase activity sensors through the application of directionally programmable D domain motifs |
| Q30278883 | Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia |
| Q34373075 | Suppression of MAPK/JNK-MTORC1 signaling leads to premature loss of organelles and nuclei by autophagy during terminal differentiation of lens fiber cells |
| Q38884906 | Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members |
| Q38894416 | Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis |
| Q38931379 | Targeted Covalent Inhibitors for Drug Design. |
| Q60915997 | Targeting JNK pathway promotes human hematopoietic stem cell expansion |
| Q90044840 | Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors |
| Q36568116 | Tead and AP1 Coordinate Transcription and Motility. |
| Q38172163 | The 2 Faces of JNK Signaling in Cancer. |
| Q34143232 | The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway |
| Q38397326 | The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. |
| Q40219694 | The coccidian parasites Toxoplasma and Neospora dysregulate mammalian lipid droplet biogenesis |
| Q38703278 | The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists. |
| Q38694843 | The mycobacterial phosphatase PtpA regulates the expression of host genes and promotes cell proliferation |
| Q88671349 | The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors |
| Q100694481 | The role of stress kinases in metabolic disease |
| Q93159737 | The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway |
| Q41915120 | Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor |
| Q91804312 | Transforming growth factor-β downregulates sGC subunit expression in pulmonary artery smooth muscle cells via MEK and ERK signaling |
| Q30153292 | Transmembrane oligomeric form of Vibrio cholerae cytolysin triggers TLR2/TLR6-dependent proinflammatory responses in monocytes and macrophages |
| Q27341886 | Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration |
| Q63976983 | Triggering MSR1 promotes JNK‐mediated inflammation in IL‐4‐activated macrophages |
| Q36158122 | Widespread JNK-dependent alternative splicing induces a positive feedback loop through CELF2-mediated regulation of MKK7 during T-cell activation |
| Q90687151 | Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion |
| Q50598064 | Wnt5a induces catabolic signaling and matrix metalloproteinase production in human articular chondrocytes |
| Q35828457 | c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression |
| Q39110390 | c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun |
| Q35921419 | cJun N-terminal kinase (JNK) phosphorylation of serine 36 is critical for p66Shc activation |
| Q89900327 | p38 MAPK signalling regulates cytokine production in IL-33 stimulated Type 2 Innate Lymphoid cells |
Search more.